Patents Examined by Shaojia Anna Jiang
-
Patent number: 9951098Abstract: Provided herein are processes for the preparation of 5-azacytidine, useful for treating, preventing, and/or managing diseases or conditions including cancer, disorders related to abnormal cell proliferation, hematologic disorders, and myelodysplastic syndromes (MDS), wherein 5-azacytidine is represented by the structure:Type: GrantFiled: March 29, 2012Date of Patent: April 24, 2018Assignee: Pharmion LLCInventors: Chinnapillai Rajendiran, Periyandi Nagarajan, Jasti Venkateswarlau
-
Patent number: 9951097Abstract: With the rise in resistance to antibiotics such as methicillin, there is a need for new drugs. The invention provides small molecules that inhibit cellular drug targets such as UPPS and FPPS by interacting with binding pockets, thereby preventing enzyme function. Compounds described herein are also active against Staphylococcus aureus (MIC90˜0.25 ?g/mL), can potently synergize with methicillin (fractional inhibitory concentration index=0.25), and are protective in a mouse infection model. The invention therefore provides numerous compounds for anti-bacterial treatments and for restoring sensitivity to drugs such as methicillin, using combination therapies.Type: GrantFiled: December 4, 2013Date of Patent: April 24, 2018Assignees: The Board of Trustees of the University of Illinois, The Regents of the University of CaliforniaInventors: Wei Zhu, Steffen Lindert, Yonghui Zhang, William Sinko, Kai Li, James Andrew McCammon, Eric Oldfield
-
Patent number: 9937134Abstract: The present invention provides compositions suitable for topical administration to a mammalian subject including sodium hyaluronate and a pharmaceutically acceptable excipient. The present invention also provides methods for making and using the same.Type: GrantFiled: July 20, 2015Date of Patent: April 10, 2018Assignee: Cypress Pharmaceuticals, Inc.Inventor: Robert Lewis
-
Patent number: 9937217Abstract: Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.Type: GrantFiled: August 10, 2015Date of Patent: April 10, 2018Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Curtis J. Henrich, Heidi R. Bokesch, Susan E. Bates, Robert W. Robey, Suneet Shukla, Suresh V. Ambudkar, Michael C. Dean, James B. McMahon
-
Patent number: 9926385Abstract: Provided are a method for producing a water-soluble cellulose ether having a low degree of polymerization and enhanced whiteness, and the like. The method includes the steps of: bringing a pulp powder having a multiplication product of less than 0.004 mm2 which is obtained by multiplying a number-average fiber length by a number-average fiber width, each measured with a Kajaani fiber length analyzer, into contact with an alkali metal hydroxide to obtain an alkali cellulose; reacting the alkali cellulose with an etherifying agent to obtain a crude water-soluble cellulose ether having a high degree of polymerization; purifying the crude water-soluble cellulose ether; drying the purified water-soluble cellulose ether; grinding the dried water-soluble cellulose ether into a water-soluble cellulose ether powder; and depolymerizing the water-soluble cellulose ether powder to obtain the water-soluble cellulose ether having a low degree of polymerization.Type: GrantFiled: July 31, 2014Date of Patent: March 27, 2018Assignee: Shin-Etsu Chemical Co., Ltd.Inventors: Akira Kitamura, Mitsuo Narita, Takuya Yokosawa, Yuichi Nishiyama
-
Patent number: 9914786Abstract: The invention relates to a dry or slurry process to prepare phosphate-crosslinked cellulose ethers from a cellulose starting material comprising the steps of adding an alkalizing agent to the cellulose starting material to achieve mercerization, adding an ethehfying agent to the reaction mixture to achieve etherification of the cellulose, and adding a crosslinking agent to the reaction mixture to achieve crosslinking of the cellulose, wherein at least part of the alkalizing agent is added to the cellulose starting material before the etherification and/or crosslinking reactions take place to obtain alkalized cellulose; the crosslinking agent and the etherifying agent are added one after the other in random order or simultaneously; the crosslinking agent is an alkali metal thmetaphosphate; and the crosslinking and etherification steps are performed at an elevated temperature.Type: GrantFiled: July 9, 2015Date of Patent: March 13, 2018Assignee: Akzo Nobel Chemicals International B.V.Inventor: Paulus Pieter De Wit
-
Patent number: 9907809Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.Type: GrantFiled: April 8, 2015Date of Patent: March 6, 2018Assignee: Vymedic, LLCInventors: Kenneth E. Phillips, Cynthia A. Winning
-
Patent number: 9896517Abstract: Provided are a low-molecular-weight fucosylated glycosaminoglycan derivative (derivative of Low molecular weight Fucosylated Glycosaminoglycan, dLFG) having anticoagulant activity, a preparation method thereof, a pharmaceutical composition comprising dLFG or a pharmaceutically acceptable salt thereof, and the use of dLFG and pharmaceutical composition thereof in preparing medicine for treating thrombotic diseases.Type: GrantFiled: December 20, 2013Date of Patent: February 20, 2018Assignee: Jiuzhitang Co., Ltd.Inventors: Jinhua Zhao, Jikai Liu, Mingyi Wu, Na Gao, Feng Lu, Zi Li
-
Patent number: 9856328Abstract: Described herein are methods for chemical modification of nitrocellulose to generate lyophobic properties which are useful in propellant compositions. Such methods include the steps of: a) dissolving neat nitrocellulose in an organic solvent; b) adding a silyl based isocyanate and a catalyst to the solution; (d) stirring the solution in a moisture free environment; e) hydrolyzing the solution by exposing said solution to moisture; and (e) adding fluorinated oxysilane. The modified nitrocellulose retains its energetic properties while exhibiting high water and organic solvent phobicity, effectively functioning as a barrier to migration or diffusion of liquid components in propellant compositions.Type: GrantFiled: June 2, 2016Date of Patent: January 2, 2018Assignee: The United States of America as Represented by the Secretary of the ArmyInventors: Henry Grau, Alexander Fadeev
-
Patent number: 9855294Abstract: The present invention relates to methods of managing weight, and treating overweight or obesity and treating or preventing diabetes in a subject in need thereof. In one embodiment, the method comprises the steps of (a) orally administering to the subject from about 0.7 g to about 4 g of crosslinked carboxymethylcellulose; and (b) orally administering to the subject at least about 100 mL of water per gram of crosslinked carboxymethylcellulose. Steps (a) and (b) are conducted prior to or with at least one meal per day.Type: GrantFiled: June 19, 2015Date of Patent: January 2, 2018Assignee: Gelesis, LLCInventors: Hassan Heshmati, Eyal S. Ron, Alessandro Sannino, Yishai Zohar
-
Patent number: 9849144Abstract: Pharmaceutical compositions comprising glutamine and trehalose for treating side effects to oncology treatments are disclosed.Type: GrantFiled: August 27, 2014Date of Patent: December 26, 2017Assignee: Healios Oncology Nutrition, LLCInventor: Peter Meade Anderson
-
Patent number: 9833466Abstract: Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of leukemia in a subject in need thereof. Provided herein are combinations comprising an HDAC inhibitor and azacitidine for the treatment of acute myelogenous leukemia in a subject in need thereof. Also provided herein are methods for treating leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor, as well as methods for treating acute myelogenous leukemia in a subject in need thereof, comprising administering to the subject an effective amount of the above combination or an HDAC inhibitor.Type: GrantFiled: July 6, 2015Date of Patent: December 5, 2017Assignee: ACETYLON PHARMACEUTICALS, INC.Inventors: Simon S. Jones, Chengyin Min, Min Yang, David Lee Tamang
-
Patent number: 9826768Abstract: A process for preparing an aqueous solution of a methylcellulose having anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, wherein s23 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 3-positions of the anhydroglucose unit are substituted with methyl groups and wherein s26 is the molar fraction of anhydroglucose units wherein only the two hydroxy groups in the 2- and 6-positions of the anhydroglucose unit are substituted with methyl groups, comprises the step of mixing the methylcellulose with an aqueous liquid at a temperature of not higher than 10° C. at a shear rate of at least 1000 s?1.Type: GrantFiled: April 8, 2014Date of Patent: November 28, 2017Assignee: Dow Global Technologies LLCInventors: Puspendu Deo, Kathryn Brown, David E. Wallick, Robert L. Sammler, Yongfu Li
-
Patent number: 9820967Abstract: One aspect of the invention provides a method of inhibiting an efflux pump in a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione, thereby inhibiting the efflux pump. Another aspect provides a method of inhibiting proliferation of a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby inhibiting the proliferation of the bacteria. Another aspect of the invention provides a method of increasing the efficacy of an antibiotic, the method comprising contacting a bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby increasing the efficacy of the antibiotic. Another aspect provides a method of inhibiting development of antibiotic resistance in a bacteria, the method comprising contacting the bacteria with 3,4-dibromopyrrole-2,5-dione and an antibiotic, thereby inhibiting development of resistance to the antibiotic.Type: GrantFiled: July 13, 2015Date of Patent: November 21, 2017Assignee: Woods Hole Oceanographic InstitutionInventors: Tracy Mincer, Kristen Whalen
-
Patent number: 9820498Abstract: An aqueous solution comprising (a) one or more mono-, di- and/or oligosaccharides and (b) a methylcellulose, wherein the methylcellulose has anhydroglucose units joined by 1-4 linkages wherein hydroxy groups of anhydroglucose units are substituted with methyl groups such that s23/s26 is 0.36 or less, is produced by i) mixing the methylcellulose with an aqueous liquid comprising one or more mono-, di- and/or oligosaccharides at a shear rate of at least 1000 s?1 or ii) mixing one or more mono-, di- and/or oligosaccharides with the methylcellulose and/or an aqueous liquid before, simultaneously with or after mixing the methylcellulose with the aqueous liquid at a shear rate of at least 1000 s?1.Type: GrantFiled: April 8, 2014Date of Patent: November 21, 2017Assignee: Dow Global Technologies LLCInventors: Puspendu Deo, Roland Adden, Matthias Knarr, Robert L. Sammler, Kathryn Brown
-
Patent number: 9808482Abstract: The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered its exclusive capacity in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, HIV, Cytomegalovirus and the virus of vesicular stomatitis.Type: GrantFiled: May 11, 2010Date of Patent: November 7, 2017Assignee: FIDIA FARMACEUTICI S.p.A.Inventors: Devis Galesso, Anna Maria Zanellato
-
Patent number: 9808530Abstract: A composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof, in combination with an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof is provided. Further, use of an excipient, selected from the group consisting of a xanthan gum, carrageenan, sodium alginate, guar gum, water dispersible cellulose (microcrystalline cellulose and sodium carboxymethylcellulose) and mixtures thereof as an anti-foaming agent in a composition comprising as the active ingredient one or more of a tiacumicin compound, a stereo-isomer thereof, a polymorph thereof or a solvate thereof is provided.Type: GrantFiled: January 14, 2014Date of Patent: November 7, 2017Assignee: Astellas Pharma Europe Ltd.Inventors: Yoshiyuki Murakami, Hikaru Saito
-
Patent number: 9803030Abstract: Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R1 (Ib) wherein X is C(O), S(O) or SO2; Y is NR1R2 or R3; R1 is C1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R2 is H or C1-6 alkyl; and R3 is C1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.Type: GrantFiled: January 11, 2008Date of Patent: October 31, 2017Assignee: GLAXOSMITHKLINE BIOLOGICALS SAInventors: Francesco Berti, Paolo Costantino, Alessandro Pianigiani
-
Patent number: 9796793Abstract: The present invention is a multilayered composite comprising porous metal oxide particles that are covalently bonded by way of inorganic ether groups to one or more sites of a first polyhydroxyl-functionalized polymer. This first polymer is in turn covalently bonded by way of inorganic ether groups to one or more sites of a second polyhydroxyl-functionalized polymer. The multilayered composites can be prepared by contacting porous inorganic-oxide particles with a sufficient amount of OH-reactive crosslinking agent to form metal oxide particles imbibed with the crosslinking agent, and then contacting the inorganic-oxide particles with a solution of polyhydroxyl-functionalized polymer under reactive conditions.Type: GrantFiled: September 5, 2014Date of Patent: October 24, 2017Assignees: The Regents of the University of California, Dow Global Technologies LLC, Rohm and Haas CompanyInventors: Joseph Jankolovits, Alexander S. Katz, Oz M. Gazit, James C. Bohling, John A. Roper, III
-
Patent number: 9797021Abstract: Compositions comprising C5 and C6 saccharides of varying degrees of polymerization and low levels of undesirable impurities, such as compounds containing sulfur, nitrogen, or metals, are disclosed.Type: GrantFiled: March 18, 2015Date of Patent: October 24, 2017Assignee: Renmatix, Inc.Inventors: Daniel Clay Floyd, Kiran Kadam, Srinivas Kilambi